Buparlisib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Transitional Cell Carcinoma of the Urothelium
Conditions
Metastatic Transitional Cell Carcinoma of the Urothelium
Trial Timeline
Mar 1, 2012 → Sep 2, 2020
NCT ID
NCT01551030About Buparlisib
Buparlisib is a phase 2 stage product being developed by Novartis for Metastatic Transitional Cell Carcinoma of the Urothelium. The current trial status is completed. This product is registered under clinical trial identifier NCT01551030. Target conditions include Metastatic Transitional Cell Carcinoma of the Urothelium.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Transitional Cell Carcinoma of the Urothelium were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02340780 | Phase 2 | Completed |
| NCT02048787 | Phase 1 | Completed |
| NCT01693614 | Phase 2 | Completed |
| NCT01551030 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Transitional Cell Carcinoma of the Urothelium